» Articles » PMID: 25551803

The Crucial Roles of Apolipoproteins E and C-III in ApoB Lipoprotein Metabolism in Normolipidemia and Hypertriglyceridemia

Overview
Specialty Biochemistry
Date 2015 Jan 1
PMID 25551803
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: To describe the roles of apolipoprotein C-III (apoC-III) and apoE in VLDL and LDL metabolism

Recent Findings: ApoC-III can block clearance from the circulation of apolipoprotein B (apoB) lipoproteins, whereas apoE mediates their clearance. Normolipidemia is sustained by hepatic secretion of VLDL and IDL subspecies that contain both apoE and apoC-III (VLDL E+C-III+). Most of this VLDL E+C-III+ is speedily lipolyzed, reduced in apoC-III content, and cleared from the circulation as apoE containing dense VLDL, IDL, and light LDL. In contrast, in hypertriglyceridemia, most VLDL is secreted with apoC-III but without apoE, and so it is not cleared until it loses apoC-III during lipolysis to dense LDL. In normolipidemia, the liver also secretes IDL and large and medium-size LDL, whereas in hypertriglyceridemia, the liver secretes more dense LDL with and without apoC-III. These pathways establish the hypertriglyceridemic phenotype and link it metabolically to dense LDL. Dietary carbohydrate compared with unsaturated fat suppresses metabolic pathways mediated by apoE that are qualitatively similar to those suppressed in hypertriglyceridemia.

Summary: The opposing actions of apoC-III and apoE on subspecies of VLDL and LDL, and the direct secretion of LDL in several sizes, establish much of the basic structure of human apoB lipoprotein metabolism in normal and hypertriglyceridemic humans.

Citing Articles

Oxidised Apolipoprotein Peptidome Characterises Metabolic Dysfunction-Associated Steatotic Liver Disease.

Mocciaro G, George A, Allison M, Frontini M, Huang-Doran I, Reiman F Liver Int. 2025; 45(2):e16200.

PMID: 39822152 PMC: 11740006. DOI: 10.1111/liv.16200.


Clinical significance of small dense low-density lipoprotein cholesterol measurement in type 2 diabetes.

Hirano T J Diabetes Investig. 2025; 16(3):370-383.

PMID: 39778086 PMC: 11871407. DOI: 10.1111/jdi.14398.


Alterations in LDL and HDL after an ischemic stroke associated with carotid atherosclerosis are reversed after 1 year.

Puig N, Camps-Renom P, Hermansson M, Aguilera-Simon A, Marin R, Bautista O J Lipid Res. 2025; 66(2):100739.

PMID: 39746448 PMC: 11815653. DOI: 10.1016/j.jlr.2024.100739.


Apolipoprotein B-containing lipoproteins in atherogenesis.

Boren J, Packard C, Binder C Nat Rev Cardiol. 2025; .

PMID: 39743565 DOI: 10.1038/s41569-024-01111-0.


APOE Protects Against Severe Infection with by Restraining Production of Neutrophil Extracellular Traps.

Liu D, Mai D, Jahn A, Murray T, Aitchison J, Gern B bioRxiv. 2024; .

PMID: 39605723 PMC: 11601580. DOI: 10.1101/2024.10.04.616580.


References
1.
Pendse A, Arbones-Mainar J, Johnson L, Altenburg M, Maeda N . Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond. J Lipid Res. 2008; 50 Suppl:S178-82. PMC: 2674752. DOI: 10.1194/jlr.R800070-JLR200. View

2.
Hiukka A, Stahlman M, Pettersson C, Levin M, Adiels M, Teneberg S . ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan. Diabetes. 2009; 58(9):2018-26. PMC: 2731525. DOI: 10.2337/db09-0206. View

3.
Sundaram M, Zhong S, Bou Khalil M, Links P, Zhao Y, Iqbal J . Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J Lipid Res. 2009; 51(1):150-61. PMC: 2789775. DOI: 10.1194/M900346-JLR200. View

4.
Mendivil C, Zheng C, Furtado J, Lel J, Sacks F . Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins. Arterioscler Thromb Vasc Biol. 2009; 30(2):239-45. PMC: 2818784. DOI: 10.1161/ATVBAHA.109.197830. View

5.
Zheng C, Khoo C, Furtado J, Sacks F . Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation. 2010; 121(15):1722-34. PMC: 3153990. DOI: 10.1161/CIRCULATIONAHA.109.875807. View